Secukinumab in the treatment of psoriasis: patient selection and perspectives

Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In Phase III clinical trials for each of these three indications, secukinumab has proven to be both highly e...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Eric J, Beck, Kristen M, Liao, Wilson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202001/
https://www.ncbi.nlm.nih.gov/pubmed/30425963
http://dx.doi.org/10.2147/PTT.S146004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202001/
https://www.ncbi.nlm.nih.gov/pubmed/30425963
http://dx.doi.org/10.2147/PTT.S146004

Ejemplares similares